J Natl Compr Canc Netw. 2018 Jun;16(6):742-774. doi: 10.6004/jnccn.2018.0055.
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.
本《NCCN Merkel 细胞癌(MCC)指南》选段重点介绍了受最新数据影响的领域,包括描述 MCC 危险因素、诊断、检查、随访以及放疗和系统治疗晚期疾病管理的部分。这些部分包括讨论使用 Merkel 细胞多瘤病毒作为生物标志物的新建议和使用检查点免疫疗法治疗转移性或不可切除疾病的新建议。MCC 完整版 NCCN 指南的下一次更新将包括有关病理学要素的更详细信息,并涉及 MCC 管理的其他方面,包括原发肿瘤和引流淋巴结区域的手术管理、作为初始治疗的放疗,以及复发的管理。